IP Verse

Genzyme competitive analysis

Loading summary...

Latest patents of Genzyme opposed by its competitors

Explore Genzyme's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3137497
Mar 5, 2025Aav Vectors For Retinal And Cns Gene Therapy1
EP2976359
Mar 23, 2022Methods For Treating Osteogenesis Imperfecta1
EP2970843
Sep 1, 2021High-Density Cell Banking Methods1
EP3047013
Aug 18, 2021Methods And Systems For Processing A Cell Culture1
EP3497207
Jan 6, 2021Methods For Detecting Aav2
EP3152299
Nov 20, 2019Seed Train Processes And Uses Thereof3
EP3133070
Aug 14, 2019Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient3
EP2371361
Aug 7, 2019Methods To Mobilize Progenitor/Stem Cells7

Latest publications and patents of Genzyme New

Explore the latest publications and patents granted to Genzyme, showcasing their recent innovations and technological advancements.

Last updated on: Oct 20, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Genzyme

EP3137497
Mar 5, 2025Aav Vectors For Retinal And Cns Gene TherapyPatent Maintained As Amended
EP2976359
Mar 23, 2022Methods For Treating Osteogenesis ImperfectaPatent Maintained As Amended
EP2970843
Sep 1, 2021High-Density Cell Banking MethodsRevoked
EP3047013
Aug 18, 2021Methods And Systems For Processing A Cell CultureGranted And Under Opposition
EP3497207
Jan 6, 2021Methods For Detecting AavOpposition Rejected
EP3152299
Nov 20, 2019Seed Train Processes And Uses ThereofRevoked
EP3133070
Aug 14, 2019Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The PatientRevoked
EP2371361
Aug 7, 2019Methods To Mobilize Progenitor/Stem CellsRevoked
EP2755999
Jan 31, 2018Anti-Aplhabetatcr AntibodyNo Opposition Filed Within Time Limit
EP2332972
Jan 10, 2018Novel Beta-Actin And Rps21 Promoters And Uses ThereofNo Opposition Filed Within Time Limit

Latest PTAB cases involving Genzyme

Discover the latest PTAB cases involving Genzyme, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 26, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Genzyme

IPR2025-01194Jun 26, 2025SAREPTA THERAPEUTICSGENZYMEPending
IPR2025-01195Jun 26, 2025SAREPTA THERAPEUTICSGENZYMEPending
IPR2023-01044Jun 30, 2023NOVARTIS GENE THERAPIESGENZYMETerminated-Settled
IPR2023-00608Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2023-00609Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2016-00460Jan 15, 2016GENZYMEGENENTECHTerminated-Settled
IPR2016-00383Dec 30, 2015GENZYMEGENENTECHInstitution Denied
IPR2013-00534Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision
IPR2013-00537Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Genzyme with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GENZYME - 1925
ACCORD HEALTHCARE39 - 4 -
GENENTECH - 87 - 65
NOVARTIS GENE THERAPIES - - 4 -